Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
NCT03491605
Summary
Immunocompetent subjects with high load of Epstein-Barr virus DNA (EBV-DNA) in peripheral blood will be enrolled and prospectively followed up to track the natural histories of the chronic high load of EBV virus. The primary goal of this study is to explore the association of peripheral high load of EBV with the hematological malignancies, and second goal is to investigate the genetic mechanisms of immune escape and tumorigenesis of chronic EBV infection.
Eligibility
Inclusion Criteria: 1. immunocompetent subjects who was found to have high EBV-DNA load (\>1×103 copies/ml)in peripheral blood during the physical examination 2. Willing to be followed up by telephone or face-to-face interview Exclusion Criteria: 1. Subjects with defined immunodeficiency 2. Subjects who have taken or are going to take immunosuppressive drugs. 3. Subjects Diagnosed a validated hematopathy 4. Subjects diagnosis as precancerous lesion or malignant tumor and the life expectancy is less than 1 year. 5. psychological illness which does not allow subjects to understand the study and participate following his own free will 6. Pregnant woman 7. no written informed consent
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT03491605